Upcoming event

TITAN trial by Prof. Chi

2019-06-07

Prof. Chi on first results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Tags: TITAN